Treatment and prevention of severe hypoglycaemia in people with diabetes: Current and new formulations of glucagon
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Some therapies for diabetes increase the risk of hypoglycaemia, in particular all insulins and insulin secretagogues, including the glinides and sulfonylureas. Hypoglycaemia remains a major limiting factor to successful glycaemic management, despite the availability of prevention options such as insulin analogues, continuous glucose monitoring, insulin pumps, and dogs that have been trained to detect hypoglycaemia. Non‐severe (self‐treated) and severe (requiring assistance for recovery) hypoglycaemia rates are higher in people with type 1 diabetes, but those with insulin‐treated type 2 diabetes are also at risk. Education and regular review are essential between people with diabetes and their caregivers and healthcare professionals about symptoms, prevention and treatment. Awareness of the potential dangers of hypoglycaemia is fundamental to the optimal management of diabetes. When therapy is intensified to achieve glycaemic targets, it is important that people at risk of severe hypoglycaemia, and particularly their caregivers, have ready access to effective treatment for hypoglycaemia emergencies. The current and potential formulations of glucagon available for treatment of severe hypoglycaemia are reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 7×
“between severe hypoglycaemia and mortality among patients with diabetes.(18,19) In the Action in Diabetes and Vascular Disease (ADVANCE) trial, death from cardiovascular and non-cardiovascular causes was associated with severe hypoglycaemia.”
BackgroundResultInfluentialSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 3×
“tions for HCPs include assessment of the risk of hypoglycaemia by clinicians and educators at every consultation with people who are being treated with insulin and insulin secretagogues, and have knowledge of the pharmacokinetics (PK) of medications.(41) People who have developed an impaired awareness of hypoglycaemia…”
BackgroundCryer, P. E., Davis, S. N., & Shamoon, H. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1902 · Cited by 1,160 · cited 1×
“cannot be regulated because of passive absorption of the injected insulin; as glucose levels fall, plasma insulin concentrations do not decline.(45) Additionally, as blood glucose falls, glucagon secretion does not increase.”
BackgroundBonds, D. E., Miller, M. E., Bergenstal, R. M., Buse, J. B., Byington, R. P., Cutler, J. A., Dudl, R. J., Ismail-Beigi, F., Kimel, A. R., Hoogwerf, B., et al. (2010) · BMJ · doi:10.1136/bmj.b4909 · Cited by 933
Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31535-5 · Cited by 893
Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Additionally, as blood glucose falls, glucagon secretion does not increase.(46) Glucagon raises blood glucose concentration in the fasting state by increasing the hepatic production of glucose, initially via glycogenolysis and subsequently via gluconeogenesis.”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s006 · Cited by 655
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“The use of continuous subcutaneous insulin infusion with insulin pumps has shown that the frequency of hypoglycaemia can be reduced,(30) and increasing sophistication with the addition of insulin suspension has further lowered the risk of severe hypoglycaemia.(31,32) Dogs that have been trained to identify the onset o…”
BackgroundHaak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Heinemann, L., Freckmann, G., Ehrmann, D., Faber-Heinemann, G., Guerra, S., Waldenmaier, D., & Hermanns, N. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30297-6 · Cited by 522
Mechanisms of hypoglycemia-associated autonomic failure in diabetes
Cryer, P. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1215228 · Cited by 433
van Beers, C. A. J., DeVries, J. H., Kleijer, S. J., Smits, M. M., Geelhoed-Duijvestijn, P. H., Kramer, M. H. H., Diamant, M., Snoek, F. J., & Serné, E. H. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30193-0 · Cited by 386
Hypoglycemia and cardiovascular risks
Frier, B. M., Schernthaner, G., & Heller, S. R. (2011) · Diabetes Care · doi:10.2337/dc11-s220 · Cited by 381
Self-citationVascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 1×
“Hypoglycaemia can induce a myriad of pathophysiological adverse effects including oxidative stress,(13) result in life-threatening events such as cardiac arrhythmias,(14) contribute to sudden cardiovascular death,(14) and cause ischaemic cerebral damage.(15,16) These”
BackgroundSelf-citationTrends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013
Lipska, K. J., Yao, X., Herrin, J., McCoy, R. G., Ross, J. S., Steinman, M. A., Inzucchi, S. E., Gill, T. M., Krumholz, H. M., & Shah, N. D. (2017) · Diabetes Care · doi:10.2337/dc16-0985 · Cited by 306
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Insulin Pump Therapy With Automated Insulin Suspension in Response to Hypoglycemia
Choudhary, P., Shin, J., Wang, Y., Evans, M. L., Hammond, P. J., Kerr, D., Shaw, J. A. M., Pickup, J. C., & Amiel, S. A. (2011) · Diabetes Care · doi:10.2337/dc10-2411 · Cited by 175
Barendse, S., Singh, H., Frier, B. M., & Speight, J. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03416.x · Cited by 161 · cited 1×
“Impaired awareness of hypoglycaemia is one of the major risk factors for severe hypoglycaemia; awareness and the physiological responses to hypoglycaemia are diminished, increasing the risk of further hypoglycaemia events.(11,20) Additional hypoglycaemia risk factors can be categorized as clinical (eg, increased insul…”
BackgroundSelf-citationKarter, A. J., Warton, E. M., Lipska, K. J., Ralston, J. D., Moffet, H. H., Jackson, G. G., Huang, E. S., & Miller, D. R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2017.3844 · Cited by 150
Hövelmann, U., Bysted, B. V., Mouritzen, U., Macchi, F., Lamers, D., Kronshage, B., Møller, D. V., & Heise, T. (2018) · Diabetes Care · doi:10.2337/dc17-1402 · Cited by 115 · cited 19×
“In a single-centre, randomized, double-blind study, the PK/PDproperties of 0.1, 0.3, 0.6 and 1.0 mg dasiglucagon, as well as its safety and tolerability, were compared with those of 0.5 and 1.0 mg GlucaGen in the treatment of insulin-induced hypoglycaemia in patients with T1D.84 Dasiglucagon produced a dose-dependent…”
BackgroundInfluentialYale, J.-F., Paty, B., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.010 · Cited by 105
Alanine and terbutaline in treatment of hypoglycemia in IDDM.
Wiethop, B. V., & Cryer, P. E. (1993) · Diabetes Care · doi:10.2337/diacare.16.8.1131 · Cited by 99
Treatment of Insulin Reactions in Diabetics
Brodows, R. G. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03350240024032 · Cited by 91
Yale, J.-F., Dulude, H., Egeth, M., Piché, C. A., Lafontaine, M., Carballo, D., Margolies, R., Dissinger, E., Shames, A. R., Kaplowitz, N., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0460 · Cited by 88 · cited 10×
“Of note, neither of these caregivers who preferred injectable glucagon managed to administer a full dose of injectable glucagon during the simulation.(68) One (6%) caregiver had no preference.”
BackgroundMethodInfluentialThe effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia
Smith, D., Pernet, A., Rosenthal, J. M., Bingham, E. M., Reid, H., Macdonald, I. A., & Amiel, S. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1513-5 · Cited by 31
Guzman, C. B., Dulude, H., Piché, C., Rufiange, M., Sadoune, A. A., Rampakakis, E., Carballo, D., Triest, M., Zhang, M. X., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13134 · Cited by 28 · cited 5×
“The effect of nasal congestion and decongestants on nasal glucagon have also been evaluated.(72) PK and PD of nasal glucagon were not significantly affected by nasal congestion or nasal decongestants.”
BackgroundMethodInfluentialChristiansen, M. P., Cummins, M., Prestrelski, S., Close, N. C., Nguyen, A., & Junaidi, K. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002137 · Cited by 22
Slama, G. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390150083016 · Cited by 3
Cited by
Glucagon, from past to present: a century of intensive research and controversies
Scheen, A. J., & Lefèbvre, P. J. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00349-7 · Cited by 44
Morettini, M., Burattini, L., Göbl, C., Pacini, G., Ahrén, B., & Tura, A. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.611147 · Cited by 27
“The interest for the study of glucagon is also due to the reason that in patients with diabetes suffering for severe hypoglycemic events the administration of glucagon, by either injection or nasal intake, is an important therapeutic option (11).”
BackgroundA New Role for Glucagon: From Secondary Hormone to Key Player
De Fano, M., Malara, M., Rucco, S., Manco, M., Fanelli, C. G., Bolli, G. B., & Porcellati, F. (2025) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104233 · Cited by 1
Metadata
- Authors
- Thieu, V. T., Mitchell, B. D., Varnado, O. J., & Frier, B. M.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-01-03
- Volume
- 22
- Issue
- 4
- Pages
- 469-479
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2995640970
- Cited by
- 44
- References
- 29
- FWCI
- 3.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.